[1]王东琴,霍浩然,秦瑞峰,等.胰腺癌患者血清 lncRNA-SNHG11的表达水平及其临床意义[J].现代检验医学杂志,2022,37(01):125-129.[doi:10.3969/j.issn.1671-7414.2022.01.025]
　WANG Dong-qin,HUO Hao-ran,QIN Rui-feng,et al.Expression Level of Serum lncRNA-SNHG11 in Patients with Pancreatic Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2022,37(01):125-129.[doi:10.3969/j.issn.1671-7414.2022.01.025]
点击复制

胰腺癌患者血清 lncRNA-SNHG11的表达水平及其临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年01期
页码:
125-129
栏目:
论　著
出版日期:
2022-01-15

文章信息/Info

Title:
Expression Level of Serum lncRNA-SNHG11 in Patients with Pancreatic Cancer and Its Clinical Significance
文章编号:
1671-7414（2022）01-125-06
作者:
王东琴; 霍浩然; 秦瑞峰; 袁增江
（河北省邯郸市中心医院普外三科, 河北邯郸 056001）
Author(s):
WANG Dong-qin;  HUO Hao-ran;  QIN Rui-feng;  YUAN Zeng-jiang
（the Third Department of General Surgery, Handan Central Hospital of Hebei Province, Hebei Handan 056001, China）
关键词:
胰腺癌; 长链非编码 RNA;  核仁小分子 RNA宿主基因 11
分类号:
R735.9；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.01.025
文献标志码:
A
摘要:
目的　探究胰腺癌患者血清长链非编码 RNA-核仁小分子 RNA宿主基因 11(lncRNA-SNHG11)的表达水平及其临床意义。方法　选择 2013年 7月～ 2015年 2月邯郸市中心医院诊治的 120例胰腺癌患者作为胰腺癌组，选择同期在邯郸市中心医院诊治的 120例胰腺炎患者作为胰腺炎组，选择同期在该院进行体检的 120例健康者作为对照组。检测胰腺癌组患者癌组织及癌旁组织 lncRNA-SNHG11表达水平，比较三组血清 lncRNA-SNHG11表达水平。分析血清 lncRNA-SNHG11表达水平与胰腺癌患者临床病理参数之间的关系。采用 Kaplan-Meier法进行生存分析。采用受试者工作特征曲线（ ROC）分析血清 lncRNA-SNHG11检测对胰腺癌的诊断价值。结果　胰腺癌组织 lncRNA-SNHG11表达水平高于癌旁正常组织（ 6.25±1.74 vs 1.21±0.35），差异有统计学意义（ t=31.107，P=0.000）。胰腺癌组血清 lncRNA-SNHG11表达水平（ 18.45±4.08）高于胰腺炎组（ 4.13±1.29），差异有统计学意义（ t=36.659，P=0.000），胰腺炎组血清 lncRNA-SNHG11表达水平高于对照组（ 1.05±0.31），差异具有统计学意义（ t=25.431，P=0.000）。有糖尿病史、有吸烟史、肥胖、饮酒、有慢性胰腺炎、有淋巴结转移、 CA199 ≥ 37U/ml，TNM分期为Ⅲ期的胰腺癌患者，血清 lncRNA-SNHG11表达水平高于无糖尿病史、无吸烟史、非肥胖、不饮酒、无慢性胰腺炎、无淋巴结转移、血清CA199＜ 37U/ ml和 TNM分期 I+II期的患者（ 20.78±4.14 vs 17.33±3.28，20.64±4.16 vs 17.27±3.97，21.45±5.03 vs 17.11±4.22，19.75±4.17 vs 17.95±3.98，20.06±4.24 vs 18.79±3.95，21.06±3.18 vs 16.19±2.37，18.99±3.08 vs 16.29±2.27和 20.97±3.23 vs 17.19±3.37），差异均有统计学意义（ t=2.272~9.586，均 P<0.05）。以 lncRNA-SNHG11表达水平的中位数为界，将患者分为 lncRNA-SNHG11低表达患者和 lncRNA-SNHG11高表达患者，Kaplan-Meier生存分析结果显示，血清 lncRNA-SNHG11低表达患者的 5年生存率明显高于高表达患者（ 21.82% vs 7.69%），差异有统计学意义（ Log-rank χ2=6.937，P<0.05）。血清 lncRNA-SNHG11检测诊断胰腺癌的曲线下面积（ AUC）为 0.912（95%CI：0.877~0.945），最佳截断值为 18.37，灵敏度和特异度分别为 0.75，0.82。CA199的 AUC为 0.854（95%CI：0.777~0.899），灵敏度和特异度分别为 0.71，0.73。结论　在胰腺癌患者中血清 lncRNA-SNHG11表达水平异常升高。血清 lncRNA-SNHG11高表达与淋巴结转移、TNM分期及胰腺癌患者预后密切相关，可作为胰腺癌患者诊断的辅助指标。
Abstract:
Objective　To investigate the expression of long non-coding RNA-small nucleolar RNA host gene 11 (lncRNASNHG11)level in patients with pancreatic cancer and its clinical significance. Methods　120 patients with pancreatic cancerwho were diagnosed and treated in Handan Central Hospital of Hebei Province from July 2013 to February 2015 were selected asthe pancreatic cancer group, 120 pancreatitis patients who were diagnosed and treated in the hospital during the same period wereselected as the pancreatitis group. and 120 healthy patients who underwent physical examination in hospital during the sameperiod were selected as the control group. The lncRNA-SNHG11 expression levels in the cancer tissues and adjacent normaltissues were detected in pancreatic cancer group. The serum lncRNA-SNHG11 expression levels of the three groups werecompared. The relationship between serum lncRNA-SNHG11 expression level and clinicopathological parameters in patientswith pancreatic cancer were analyzed. Kaplan-Meier method was used for survival analysis. The diagnostic value of serumlncRNA-SNHG11 expression levels in pancreatic cancer was analyzed by using the receiver operating curve (ROC) curve.Results　 The lncRNA-SNHG11 expression level in pancreatic cancer tissues was higher than that in the adjacent normal tissues（6.25±1.74 vs 1.21±0.35）, and the difference was statistically significant（t=31.107, P=0.000）.The expressionlevel of lncRNA-SNHG11 in pancreatic cancer group （18.45±4.08） was higher than that in parcreatitis group（4.13±1.29）,the difference was statistically significant(t=36.659, P=0.000), and the expression level of lncRNA-SNHG11 in parcreatitis groupwas higher than that in control group(1.05±0.31), the difference was statistically significant(t=25.431, P=0.000). Patients withdiabetes, smoking, obesity, drinking, chronic pancreatitis, lymph node metastasis, CA199 ≥ 37U/ml, TNM stage III pancreaticcancer and lncRNA-SNHG11 expression levels were higher than those without diabetes, smoking, non obesity, drinking, chronicpancreatitis, lymph node metastasis, CA199 < 37U/ml and TNM stage I + II（20.78±4.14 vs 17.33±3.28, 20.64±4.16 vs17.27±3.97, 21.45±5.03 vs 17.11±4.22, 19.75±4.17 vs 17.95±3.98, 20.06±4.24 vs 18.79±3.95, 21.06±3.18 vs16.19±2.37, 18.99±3.08 vs 16.29±2.27and 20.97±3.23 vs 17.19±3.37）,and the difference were statistically significant(t=2.272~9.586, all P<0.05). The median of the lncRNA-SNHG11 expression level was used as the boundary, patients weredivided into patients with low expression of lncRNA-SNHG11 and patients with high expression of lncRNA-SNHG11. Kaplan-Meier survival analysis showed that the 5-year survival rate of patients with low expression of serumlncRNA-SNHG11 wassignificantly higher than that of patients with high expression of lncRNA-SNHG11 （21.82% vs 7.69%）,and the difference wasstatistically significant (Log-rank χ2=6.937, P<0.05). The area under curve (AUC) of serum lncRNA-SNHG11 in the diagnosis ofpancreatic cancer was 0.912(95%CI: 0.877~0.945), the optimal cut-off value was 18.37, and the sensitivity and specificity were0.75 and 0.82, respectively. The AUC of CA199 was 0.854(95%CI: 0.777~0.899), and the sensitivity and specificity were 0.71and 0.73 respectively. Conclusion　Serum lncRNA-SNHG11 expression was abnormally elevated in patients with pancreaticcancer. The high expression of serum lncRNA-SNHG11 was closely related to lymph node metastasis, TNM stage and prognosisof patients with pancreatic cancer, which may serve as an auxiliary indicator for the diagnosis of patients with pancreatic cancer.

参考文献/References:

[1] 方昀，来梦茹，葛宇清，等．胰腺癌药物治疗的现状与展望[J]．中国中药杂志,2019, 44(8):1509-1516.FANG Yun，LAI Mengru，GE Yuqing,et al. Currentstatus and future prospect of pharmacotherapy forpancreatic cancer [J]. China Journal of Chinese MateriaMedica,2019, 44(8):1509-1516.
[2] CHU L C, GOGGINS M G, FISHMAN E K. Diagnosisand detection of pancreatic cancer[J]. Cancer Journal(Sudbury, Mass.), 2017, 23(6): 333-342.
[3] 许勇，李波，林强，等．MicroRNA-92a 在胰腺癌中的表达及对肿瘤生长的影响[J]．中国现代医学杂志,2019, 29(3):52-56.XU Yong, LI Bo, LING Qiang, et al. Effect ofmicroRNA-92a on pancreatic ductal adenocarcinoma [J].China Journal of Modern Medicine, 2019, 29(3):52-56.
[4] 杨静，周颖，金咏梅，等．胰腺癌患者循环肿瘤细胞及TLR4,TLR9,MYB88 的表达水平与其化疗效果及转移、复发的关系[J]. 现代生物医学进展,2017,17(28)：5524-5527, 5556．YANG Jing, ZHOU Ying, JIN Yongmei, et al.Expressions of TLR4, TLR9 and MYB88 signalingin CTC of patients with pancreatic carcinoma andits relationship with chemotherapy, metastasis andrecurrence [J]. Progress in Modern Biomedicine, 2017,17(28):5524-5527,5556.
[5] ZHANG Lulu, SANAGAPALLI S, STOITA A.Challenges in diagnosis of pancreatic cancer[J]. WorldJournal of Gastroenterology, 2018, 24(19): 2047-2060.
[6] BHAN A, SOLEIMANI M, MANDAL S S. Longnoncoding RNA and cancer: a new paradigm[J]. CancerResearch, 2017, 77(15): 3965-3981.
[7] LI Jiaqi, GAO Jing, KAN Ao, et al. SNHG and UCA1as prognostic molecular biomarkers in hepatocellularcarcinoma: recent research and meta-analysis[J].Minerva Medica, 2017, 108(6): 568-574.
[8] HUANG Weizhen, DONG Shaoting, CHA Yinlian, etal. SNHG11 promotes cell proliferation in colorectalcancer by forming a positive regulatory loop withc-Myc[J]. Biochemical and Biophysical ResearchCommunications, 2020, 527(4): 985-992.
[9] MCGUIGAN A, KELLY P, TURKINGTON R C, etal. Pancreatic cancer: A review of clinical diagnosis,epidemiology, treatment and outcomes[J]. WorldJournal of Gastroenterology, 2018, 24(43): 4846-4861.
[10] FRANKIW L, BALTIMORE D, LI Guideng.A l t e r n a t i v e m R N A s p l i c i n g i n c a n c e rimmunotherapy[J]. Nature Reviews Immunology, 2019,19(11): 675-687.
[11] GANJU A, KHAN S, HAFEEZ B B, et al. miRNAnanotherapeutics for cancer[J]. Drug Discovery Today,2017, 22(2): 424-432.
[12] CHEN Qinnan, WEI Chenchen, WANG Zhaoxia,et al. Long non-coding RNAs in anti-cancer drugresistance[J]. Oncotarget, 2017, 8(1): 1925-1936.
[13] 吴良银，李文丽，刘俊．肝细胞癌患者生存预后相关长链非编码RNA(LncRNA) 的生物信息学分析[J].现代检验医学杂志,2019,34(4):18-21.WU Liangyin,LI Wenli，LIU Jun. Bioinformaticsanalysis of long-chain non-coding RNA related tosurvival and prognosis in patients with hepatocellularcarcinoma [J]. Journal of Modern LaboratoryMedicine,2019,34(4):18-21.
[14] 孟祥鹏，马佳，王宝胜．lncRNA/miRNA 在胰腺癌发生发展中的研究进展[J]. 现代肿瘤医学,2020,28(22):3999-4002.MENG Xiangpeng, MA Jia, WANG Baosheng. Researchprogress of lncRNA/miRNA in pancreaticcancer development [J]. Journal of Modern Oncology,2020,28(22):3999-4002.
[15] 中华医学会外科学分会胰腺外科学组．胰腺癌诊治指南[J]．中华肝胆外科杂志, 2008, 14(3):198-200.Division of Pancreatic Surgery，Branch of Sugery，Chinese Medical Association. Guideline for diagnosisand treatment of pancreatic cancer [J]. Chinese Journalof Hepatobiliary Surgery, 2008, 14(3):198-200.
[16] 王辉，马明亮，张德刚，等．SNHG11 通过激活Wnt信号通路促进骨肉瘤细胞增殖[J]．中国骨与关节杂志,2019, 8(1):66-70.WANG Hui, MA Mingliang, ZHANG Degang, et al.SNHG11 promotion in osteosarcoma cell proliferationby activating Wnt pathway [J]. Chinese Journal of Boneand Joint,2019, 8(1):66-70.
[17] ZHAN Tianzuo, RINDTORFF N, BOUTROS M. Wntsignaling in cancer[J]. Oncogene, 2017, 36(11): 1461-1473.
[18] KASPRZAK A. Angiogenesis-related functions ofWnt signaling in colorectal carcinogenesis[J]. Cancers,2020, 12(12): 3601.
[19] YANG Jinshou, REN Bo, YANG Gang, et al. Theenhancement of glycolysis regulates pancreatic cancermetastasis[J]. Cellular and Molecular Life Sciences,2020, 77(2): 305-321.
[20] YE Guomei , GUO Liqiang，XING Yanfei，et al.Identification of prognostic biomarkers of prostatecancer with longnon-coding RNA-mediated competitiveendogenous RNA network[J]. Experimental andTherapeutic Medicine, 2019, 17(4) : 3035-3040.
[21] XU Wei, ZHOU Gai, WANG Huizhi, et al. CirculatinglncRNA SNHG11 as a novel biomarker for earlydiagnosis and prognosis of colorectal cancer[J].International Journal of Cancer, 2020, 146(10): 2901-2912.
[22] SONG Mengqiu, BODE A M, DONG Zigang, et al.AKT as a therapeutic target for cancer[J]. CancerResearch, 2019, 79(6): 1019-1031.
[23] CHANDRA GUPTA S, NANDAN TRIPATHI Y.Potential of long non-coding RNAs in cancer patients:From biomarkers to therapeutic targets[J]. InternationalJournal of Cancer, 2017, 140(9): 1955-1967.
[24] DONG Peixin, XIONG Ying, YUE Junming,et al.Exploring lncRNA-mediated regulatorynetworks in endometrial cancer cells and the tumormicroenvironment: advances and challenges[J].Cancers, 2019, 11(2): 234.

相似文献/References:

[1]党珊a,周健a,杨帆b,等.胰腺癌组织中缺氧诱导因子-2α的表达及临床意义[J].现代检验医学杂志,2015,30(06):32.[doi:10.3969/j.issn.1671-7414.2015.06.009]
　DANG Shana,ZHOU Jiana,YANG Fanb,et al.Expression of Hypoxia Inducible Factor 2α in Pancreatic Carcinoma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2015,30(01):32.[doi:10.3969/j.issn.1671-7414.2015.06.009]
[2]韦 莉,缪淑贤,王 敏,等.胰腺癌患者血清尿酸、肌酐水平检测及尿酸/肌酐比值的临床意义[J].现代检验医学杂志,2019,34(04):99.[doi:10.3969/j.issn.1671-7414.2019.04.024]
　WEI Li,MIAO Shu-xian,WANG Min,et al.Clinical Significance of Serum Uric Acid,Creatinine and Uric Acid/Creatinine Ratio in Pancreatic Ductal Adenocarcinoma[J].Journal of Modern Laboratory Medicine,2019,34(01):99.[doi:10.3969/j.issn.1671-7414.2019.04.024]
[3]邢瑞青,彭道荣,刘　杨.血清CA199，KL-6和PIVKA-Ⅱ水平联合检测在胰腺癌诊断中的应用价值分析[J].现代检验医学杂志,2021,36(05):100.[doi:10.3969/j.issn.1671-7414.2021.05.022]
　XING Rui-qing,PENG Dao-rong,LIU Yang.Application Value of Combined Detection of Serum CA199,KL-6 andPIVKA -Ⅱ Levels in the Diagnosis of Patients with Pancreatic Cancer[J].Journal of Modern Laboratory Medicine,2021,36(01):100.[doi:10.3969/j.issn.1671-7414.2021.05.022]
[4]王军堂a,齐普良a,张金刚a,等.hsa_circ_0006950 调控miR-124-3p/EZH2 轴促进胰腺癌细胞增殖与迁移的机制研究[J].现代检验医学杂志,2022,37(05):93.[doi:10.3969/j.issn.1671-7414.2022.05.019]
　WANG Jun-tanga,QI Pu-lianga,ZHANG Jin-ganga,et al.Mechanism of hsa_circ_0006950 Regulating miR-124-3p /EZH2 Axis to Promote the Proliferation and Migration of Pancreatic Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(01):93.[doi:10.3969/j.issn.1671-7414.2022.05.019]
[5]张莉娜,张霁雯,罗 酩,等.胰腺癌组织CTTN 和miR-545-3p 表达水平及其与临床病理和预后的相关性研究[J].现代检验医学杂志,2022,37(06):99.[doi:10.3969/j.issn.1671-7414.2022.06.018]
　ZHANG Li-na,ZHANG Ji-wen,LUO Ming,et al.Expression Levels of CTTN and miR-545-3p in Pancreatic Cancer Tissues and Their Correlation with Clinicopathology and Prognosis[J].Journal of Modern Laboratory Medicine,2022,37(01):99.[doi:10.3969/j.issn.1671-7414.2022.06.018]
[6]张立洁a,彭 泉b.基于GEO 数据库筛选慢性胰腺炎恶变过程中关键miRNA 和ceRNA 网络构建[J].现代检验医学杂志,2023,38(02):18.[doi:10.3969/j.issn.1671-7414.2023.02.004 ]
　ZHANG Li-jiea,PENG Quanb.Screening of Key miRNAs and Construction of Competing Endogenous RNA Network Involved in the Progression from Chronic Pancreatitis to Pancreatic Cancer Based on GEO Database[J].Journal of Modern Laboratory Medicine,2023,38(01):18.[doi:10.3969/j.issn.1671-7414.2023.02.004 ]
[7]檀占海,陈建荣,张吉发,等.胰腺癌组织中METTL14 和GFPT1 的水平表达与临床预后价值研究[J].现代检验医学杂志,2023,38(05):99.[doi:10.3969/j.issn.1671-7414.2023.05.019]
　TAN Zhanhai,CHEN Jianrong,ZHANG Jifa,et al.Expression of METTL14 and GFPT1 in Pancreatic Cancer and Their Clinical Prognostic Value[J].Journal of Modern Laboratory Medicine,2023,38(01):99.[doi:10.3969/j.issn.1671-7414.2023.05.019]
[8]夏菊芳,刘 洪.胰腺癌组织中KYNU mRNA 的表达及其与免疫浸润和预后的相关性研究[J].现代检验医学杂志,2024,39(02):57.[doi:10.3969/j.issn.1671-7414.2024.02.011]
　XIA Jufang,LIU Hong.Expression of KYNU mRNA in Pancreatic Cancer Tissue and Its Correlation with Immune Infiltration and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(01):57.[doi:10.3969/j.issn.1671-7414.2024.02.011]

备注/Memo

备注/Memo:
基金项目：河北省科技计划项目（152777210）; 河北省邯郸市科学技术研究与发展计划（1823208051ZC）。
作者简介：王东琴(1971-), 女, 本科, 副主任医师，研究方向，肝胆胰外科，E-mail:15932031921@163.com。
更新日期/Last Update: 1900-01-01